First-in-human dual-epitope nanobody anti-CD5 CAR-T for relapsed/refractory T-ALL/PTCL: Phase I dose-escalation and expansion results from the CONQUER trial.

YTS105 - BriSTAR Immunotech

https://www.asco.org/abstracts-presentations/258867

Meng Lv; Xiao-Jun Huang; Xiangyu Zhao; Lin Wang; Wang Mingkun; Ting Zhao; Xu-Ying Pei; Xiao-Dong Mo; Yuqian Sun; Xiao-Hui Zhang; Na Kuang

Apr 21, 2026